Nuclear Factor-κB P65 Regulates Glutaminase 1 Expression in Human Hepatocellular Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2018 Jul 11

PMID 29988727

Citations 13

Authors

Meng Dong

Lin Miao

Fengmei Zhang

Shengshui Li

Jingzhi Han

Ruohui Yu

Shuo Qie

Affiliations

Soon will be listed here.

Abstract

Background: Glutaminase (GLS), the key enzyme that catalyzes glutamine catabolism, facilitates the production of energy, building blocks, and factors resisting stresses. Two isoforms of GLS have been identified: GLS1 and GLS2. Elevated GLS1 contributes to tumorigenesis and tumor progression. This study investigates the molecular mechanism by which GLS1 is regulated in human hepatocellular carcinoma (HCC).

Methods: Online databases were investigated to search for factors that co-overexpress with . siRNA knockdown or chemical compounds were utilized to manipulate the activation or inactivation of nuclear factor-κB (NF-κB) p65 signaling. Both the mRNA and protein levels of were detected. The biological and clinical importance of p65-GLS1 in HCC was also demonstrated.

Results: NF-κB p65 regulates GLS1 expression in HCC cells. Knockdown or suppression of GLS1 compromises HCC cell proliferation. Elevated GLS1 expression correlates with neoplasm histological grade, and the dysregulation of p65-GLS1 is associated with poor prognosis in human HCC patients.

Conclusion: GLS1 can be developed as a diagnostic and therapeutic target for human HCC.

Citing Articles

Glutamine metabolism, a double agent combating or fuelling hepatocellular carcinoma.

Ziki R, Colnot S JHEP Rep. 2024; 6(5):101077.

PMID: 38699532 PMC: 11063524. DOI: 10.1016/j.jhepr.2024.101077.

Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.

Zhang L, Su K, Liu Q, Li B, Wang Y, Cheng C BMC Cancer. 2023; 23(1):1081.

PMID: 37946141 PMC: 10633901. DOI: 10.1186/s12885-023-11601-y.

Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer.

Hoskin A, Holt A, Legge D, Collard T, Williams A, Vincent E Explor Target Antitumor Ther. 2023; 4(4):600-615.

PMID: 37720350 PMC: 10501897. DOI: 10.37349/etat.2023.00155.

Bioinformatic Analysis of The Prognostic Value of A Panel of Six Amino Acid Transporters in Human Cancers.

Liu Y, Xiong H, Yan C, Wang Y, Cao W, Qie S Cell J. 2023; 25(9):613-624.

PMID: 37718764 PMC: 10520983. DOI: 10.22074/cellj.2023.2004011.1319.

BAIAP2L2 is a novel prognostic biomarker related to migration and invasion of HCC and associated with cuprotosis.

Wei H, Yang J, Chen X, Liu M, Zhang H, Sun W Sci Rep. 2023; 13(1):8692.

PMID: 37248248 PMC: 10227027. DOI: 10.1038/s41598-023-35420-0.

References

Altman B, Stine Z, Dang C . From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016; 16(10):619-34. PMC: 5484415. DOI: 10.1038/nrc.2016.71. View

Zhang C, Liu J, Zhao Y, Yue X, Zhu Y, Wang X . Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. Elife. 2016; 5:e10727. PMC: 4749555. DOI: 10.7554/eLife.10727. View

Sun B, Qie S, Zhang S, Sun T, Zhao X, Gao S . Role and mechanism of vasculogenic mimicry in gastrointestinal stromal tumors. Hum Pathol. 2008; 39(3):444-51. DOI: 10.1016/j.humpath.2007.07.018. View

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

Yin C, Qie S, Sang N . Carbon source metabolism and its regulation in cancer cells. Crit Rev Eukaryot Gene Expr. 2012; 22(1):17-35. PMC: 4505802. DOI: 10.1615/critreveukargeneexpr.v22.i1.20. View

Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y . Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007; 178(1):93-105. PMC: 2064426. DOI: 10.1083/jcb.200703099. View

Xiang Y, Stine Z, Xia J, Lu Y, OConnor R, Altman B . Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest. 2015; 125(6):2293-306. PMC: 4497742. DOI: 10.1172/JCI75836. View

Xu P, Oosterveer M, Stein S, Demagny H, Ryu D, Moullan N . LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer. Genes Dev. 2016; 30(11):1255-60. PMC: 4911925. DOI: 10.1101/gad.277483.116. View

Qie S, Majumder M, Mackiewicz K, Howley B, Peterson Y, Howe P . Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma. Nat Commun. 2017; 8(1):1534. PMC: 5688124. DOI: 10.1038/s41467-017-01199-8. View

10.

Wang D, Meng G, Zheng M, Zhang Y, Chen A, Wu J . The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells. PLoS One. 2016; 11(11):e0166423. PMC: 5105986. DOI: 10.1371/journal.pone.0166423. View

11.

Gao P, Tchernyshyov I, Chang T, Lee Y, Kita K, Ochi T . c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009; 458(7239):762-5. PMC: 2729443. DOI: 10.1038/nature07823. View

12.

Wang J, Erickson J, Fuji R, Ramachandran S, Gao P, Dinavahi R . Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18(3):207-19. PMC: 3078749. DOI: 10.1016/j.ccr.2010.08.009. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Rhodes D, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D . ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6(1):1-6. PMC: 1635162. DOI: 10.1016/s1476-5586(04)80047-2. View

15.

Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L . MiRNA-192 [corrected] and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLoS Genet. 2015; 11(12):e1005726. PMC: 4692503. DOI: 10.1371/journal.pgen.1005726. View

16.

Yu D, Shi X, Meng G, Chen J, Yan C, Jiang Y . Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget. 2015; 6(10):7619-31. PMC: 4480704. DOI: 10.18632/oncotarget.3196. View

17.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

18.

Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, Martinez-Torteya A, Chacolla-Huaringa R, Rodriguez-Barrientos A . SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013; 8(9):e74250. PMC: 3774754. DOI: 10.1371/journal.pone.0074250. View

19.

Thangavelu K, Pan C, Karlberg T, Balaji G, Uttamchandani M, Suresh V . Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012; 109(20):7705-10. PMC: 3356676. DOI: 10.1073/pnas.1116573109. View

20.

Rathore M, Saumet A, Rossi J, de Bettignies C, Tempe D, Lecellier C . The NF-κB member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol. 2012; 44(9):1448-56. DOI: 10.1016/j.biocel.2012.05.011. View